Skip to main content
. 2023 Aug 14;14(4):1837–1848. doi: 10.21037/jgo-23-486

Figure 3.

Figure 3

Subgroup analysis of OS in overall population at final analysis. HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; ICI, immune checkpoint inhibitor; OS, overall survival.